Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amoxicillin clavulanate is a combination antibiotic consisting of amoxicillin, a penicillin-class antibiotic, and clavulanic acid (clavulanate), a beta-lactamase inhibitor. Amoxicillin works by inhibiting bacterial cell wall synthesis, leading to bacterial death. However, some bacteria produce beta-lactamase enzymes that can inactivate amoxicillin; clavulanic acid inhibits these enzymes, thereby extending the spectrum of activity of amoxicillin against beta-lactamase-producing organisms. This combination is used to treat various bacterial infections including those of the ear, lungs (such as pneumonia and bronchitis), sinuses, skin and soft tissue, urinary tract infections, animal bites, and others. It is available in oral and intravenous formulations[1][2][3][4][5]. The drug was first approved for use in the United States in 1984[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin clavulanate.